Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

Kerkelä R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T.

Nat Med. 2006 Aug;12(8):908-16.

PMID:
16862153
2.

Another look at imatinib mesylate.

Strebhardt K, Ullrich A.

N Engl J Med. 2006 Dec 7;355(23):2481-2. No abstract available.

PMID:
17151370
3.

Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress.

Ma H, Jones KR, Guo R, Xu P, Shen Y, Ren J.

Clin Exp Pharmacol Physiol. 2010 Apr;37(4):460-5. doi: 10.1111/j.1440-1681.2009.05323.x.

PMID:
19878217
4.

Ageing is a risk factor in imatinib mesylate cardiotoxicity.

Maharsy W, Aries A, Mansour O, Komati H, Nemer M.

Eur J Heart Fail. 2014 Apr;16(4):367-76.

5.
6.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Rosti G, Martinelli G, Baccarani M.

Nat Med. 2007 Jan;13(1):15; author reply 15-6. No abstract available.

PMID:
17206121
7.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Atallah E, Kantarjian H, Cortes J.

Nat Med. 2007 Jan;13(1):14; author reply 15-6. No abstract available.

PMID:
17206119
8.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Hatfield A, Owen S, Pilot PR.

Nat Med. 2007 Jan;13(1):13; author reply 15-6. No abstract available.

PMID:
17206118
9.

In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.

Gambacorti-Passerini C, Tornaghi L, Franceschino A, Piazza R, Corneo G, Pogliani E.

Nat Med. 2007 Jan;13(1):13-4; author reply 15-6. No abstract available. Erratum in: Nat Med. 2007 Feb;13(2):224. Gambacorti, Carlo [corrected to Gambacorti-Passerini, Carlo].

PMID:
17206117
10.

Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase.

Hu W, Lu S, McAlpine I, Jamieson JD, Lee DU, Marroquin LD, Heyen JR, Jessen BA.

Toxicol Sci. 2012 Sep;129(1):188-99. doi: 10.1093/toxsci/kfs192.

11.

Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies.

Wolf A, Couttet P, Dong M, Grenet O, Heron M, Junker U, Laengle U, Ledieu D, Marrer E, Nussher A, Persohn E, Pognan F, Rivière GJ, Roth DR, Trendelenburg C, Tsao J, Roman D.

Leuk Res. 2010 Sep;34(9):1180-8. doi: 10.1016/j.leukres.2010.01.004.

PMID:
20122731
12.

Modulation of caspase-independent cell death leads to resensitization of imatinib mesylate-resistant cells.

Lavallard VJ, Pradelli LA, Paul A, Bénéteau M, Jacquel A, Auberger P, Ricci JE.

Cancer Res. 2009 Apr 1;69(7):3013-20. doi: 10.1158/0008-5472.CAN-08-2731.

15.

Strategies for overcoming imatinib mesylate resistance in chronic myelogenous leukemia.

Singh T, Casson C.

Am J Ther. 2007 Sep-Oct;14(5):484-7.

PMID:
17890939
16.

Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.

François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P.

Am J Kidney Dis. 2008 Feb;51(2):298-301. doi: 10.1053/j.ajkd.2007.10.039.

PMID:
18215707
17.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026.

PMID:
18571721
18.

Cardiotoxicity of the anticancer therapeutic agent bortezomib.

Nowis D, Maczewski M, Mackiewicz U, Kujawa M, Ratajska A, Wieckowski MR, Wilczyński GM, Malinowska M, Bil J, Salwa P, Bugajski M, Wójcik C, Siński M, Abramczyk P, Winiarska M, Dabrowska-Iwanicka A, Duszyński J, Jakóbisiak M, Golab J.

Am J Pathol. 2010 Jun;176(6):2658-68. doi: 10.2353/ajpath.2010.090690.

19.

Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.

White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T.

J Clin Oncol. 2007 Oct 1;25(28):4445-51.

PMID:
17906206
20.

Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.

Ishikawa I, Kato C, Harigae H, Sugawara T, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Miyamura K, Sasaki T.

Tohoku J Exp Med. 2006 Dec;210(4):355-63.

Items per page

Supplemental Content

Support Center